The dysfunction in how Australia and New Zealand approach pharmaceutical reimbursement is not just procedural. It is rooted in how these systems think about themselves and the myths that sustain their authority. For years, debates over these programs have been channelled into technical terrain that the institution controls and comfortably defends. Institutions shield themselves through their own mythology, recasting policy choices as unquestionable truths. Real reform depends on challenging those myths and exposing the political decisions they conceal.
Process as power - how our institutions defend policy decisions by making them untouchable truths
October 30, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
LifeSciences Australia honours outstanding professionals at MTP Sector Awards 2026
June 12, 2026 - - Latest News -
'The changes could cause irreversible damage to our vibrant and world-leading biotech, medtech and health tech sector'
June 12, 2026 - - Australian Biotech -
The opportunity to change the conversation, the negotiating dynamic, and take some control
June 12, 2026 - - Latest News -
State and Territory ministers warn against centralising NDIS power
June 12, 2026 - - Latest News -
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech

